Dynamic Risk Profiling in Colorectal Surveillance: Shifting the Paradigm
The landscape of colorectal cancer (CRC) prevention has been fundamentally transformed by the widespread adoption of screening colonoscopy. However, the success of these programs has created a new clinical challenge: the management of a burgeoning population of patients post-polypectomy. Current surveillance guidelines from the U.S. Multi-Society Task Force (USMSTF) and the European Society of Gastrointestinal Endoscopy (ESGE) primarily stratify risk based on baseline adenoma characteristics—size, number, and histology. While these factors are predictive of short-term recurrence, they often fail to account for the temporal heterogeneity of risk and the influence of patient-specific demographic and metabolic factors over a lifetime. A landmark study published in JAMA Network Open by Awan et al. (2026) provides a critical reassessment of these risks, utilizing a massive longitudinal cohort to demonstrate that adenoma recurrence is a time-dependent phenomenon influenced heavily by race, sex, and obesity.
Highlights
– High-grade dysplasia (HGD) is the strongest predictor of early recurrence (aHR 4.00 within 5 years) but its predictive value vanishes after 10 years, suggesting a window of aggressive biological activity or missed lesions.
– Villous histology exhibits a unique biphasic risk pattern, with an initial elevation in recurrence risk that re-emerges significantly after a decade of follow-up (aHR 2.71).
– Obesity (BMI >30) serves as a persistent, non-attenuating risk factor, increasing recurrence probability steadily across all surveillance intervals.
– Female patients with initial high-risk adenomas face a significantly higher late-term recurrence risk than their male counterparts after the 10-year mark, challenging current assumptions about gender-neutral surveillance intervals.
The Limitations of Static Surveillance Guidelines
For decades, clinical practice has relied on the assumption that the biological risk conferred by an adenoma is relatively constant or predictable based on its baseline morphology. If a patient presents with a high-risk adenoma (HRA), they are typically funneled into a 3-year surveillance interval, while those with low-risk adenomas (LRA) are pushed to 7 or 10 years. However, this static approach ignores the dynamic nature of the colonic mucosa and the systemic factors that drive tumorigenesis.
The clinical burden of surveillance is immense, often straining endoscopy units and subjecting patients to repeated invasive procedures. Conversely, extending intervals too aggressively based solely on a single ‘clean’ follow-up may miss late-emerging risks in specific sub-populations. The unmet medical need addressed by Awan et al. is the lack of granularity in how we predict long-term (10+ year) outcomes, particularly for patients who may have metabolic comorbidities or specific demographic profiles that alter their risk trajectory.
Methodological Rigor: The Longitudinal Cohort Approach
This retrospective cohort study represents one of the largest and most comprehensive analyses of adenoma recurrence to date. Drawing from a tertiary medical center database, the researchers included 59,667 adults who underwent their first colonoscopic polypectomy between 1990 and 2024. The mean age of the cohort was 60 years, with a nearly equal distribution of sex (49.3% female) and a significant representation of non-Hispanic Black patients (10.0%).
The primary outcome was recurrence-free survival, defined as the time from the index polypectomy to the first histologically confirmed recurrence. To move beyond traditional static models, the investigators employed time-varying coefficient Cox models. This statistical approach is crucial because it allows the hazard ratio of a specific variable (like HGD or obesity) to change over time rather than assuming it remains constant throughout the follow-up period. The follow-up was stratified into three distinct windows: early (<5 years), midterm (5–10 years), and late (≥10 years).
Temporal Heterogeneity: When Risk Fades or Re-emerges
The study’s most provocative findings lie in the divergent temporal patterns of different histopathologic features.
High-Grade Dysplasia: The Early Threat
Patients with HGD at baseline faced a nearly four-fold increase in recurrence risk during the first five years (aHR 4.00; 95% CI, 3.56-4.50). However, by the 10-year mark, this association became statistically non-significant. This suggests that HGD may be a marker of immediate mucosal instability or represent a higher likelihood of synchronous, undetected lesions that manifest shortly after the index procedure. Once a patient with HGD has cleared several surveillance rounds, their risk profile may eventually normalize toward the baseline of the general population.
Villous Histology: The Biphasic Risker
In contrast, villous histology showed a biphasic pattern. While it conferred high risk early on (aHR 2.89), it did not fade away like HGD. Instead, after a period of relative stability in the midterm, the risk re-emerged after 10 years (aHR 2.71; 95% CI, 2.15-3.41). This ‘second wave’ of risk implies that villous features may be indicative of a more profound ‘field effect’ or a specific molecular pathway (such as the serrated pathway or CIMP-high phenotypes) that continues to generate new lesions over a longer horizon.
The Persistent Impact of Metabolic Health and Demographic Factors
While histopathology often takes center stage in gastroenterology, this study highlights the undeniable role of systemic patient factors.
Obesity as a Constant Driver
Obesity (BMI >30) was found to be a ‘constant’ risk factor. Unlike HGD, the risk associated with obesity did not attenuate over time. It maintained an aHR of approximately 1.16 in the early phase and 1.22 in the late phase. This suggests that the pro-inflammatory and insulin-resistant environment associated with obesity provides a continuous stimulus for adenoma formation, regardless of how many polyps are removed. For clinicians, this reinforces the need to incorporate lifestyle counseling and metabolic management into the long-term CRC prevention strategy.
The Gender Divergence in Late Surveillance
One of the most surprising findings was the sex-based difference in late-term recurrence. Female patients who initially presented with high-risk adenomas had a significantly higher hazard of late recurrence (aHR 1.73) compared to male patients (aHR 1.29) after 10 years. This finding challenges the general trend where men are often considered at higher risk for CRC. It raises questions about whether post-menopausal hormonal changes or different adherence patterns to follow-up may play a role in the delayed risk seen in women.
Expert Commentary and Clinical Implications
The results of this study suggest that our current ‘one-and-done’ risk stratification at the time of initial polypectomy is insufficient. If a patient’s risk for recurrence changes depending on whether they are 3, 7, or 12 years out from their procedure, our surveillance intervals should be equally dynamic.
Mechanistic Insights
From a biological perspective, the re-emergence of risk in villous adenomas after 10 years is particularly interesting. It suggests that the colonic environment in these patients remains predisposed to neoplasia. This could be due to epigenetic changes in the mucosa (field cancerization) that are not ‘cured’ by simple polypectomy. In contrast, the attenuation of HGD risk suggests that HGD might be a focal rather than a field phenomenon, or that current intensive surveillance for HGD is successfully ‘clearing’ the risk within the first decade.
Health Equity and Personalized Care
By identifying that non-Hispanic Black patients and obese individuals maintain higher baseline risks, the study provides a roadmap for more equitable care. If certain populations have a higher ‘floor’ of risk, they may require more frequent surveillance even if their baseline adenoma was small or lacked high-risk histology. This moves the needle toward a ‘precision surveillance’ model where the frequency of colonoscopy is determined by a combination of what was found in the colon and who the patient is.
Study Limitations
Despite its size, the study is limited by its retrospective nature and its origin from a single tertiary medical center, which may introduce selection bias. Additionally, while the study controlled for many factors, it did not have access to molecular data (e.g., BRAF mutations or MSI status) which could further refine the temporal risk categories.
Conclusion
The work by Awan et al. serves as a vital reminder that the risk of colorectal neoplasia is a marathon, not a sprint. The discovery that high-grade dysplasia is an early-phase risk while villous histology and obesity are long-term drivers should prompt a re-evaluation of how we counsel patients after their first decade of surveillance. As we move toward more personalized medicine, the integration of demographic data, metabolic health, and time-varying histopathologic risks will be essential to ensure that we are neither over-screening low-risk individuals nor under-screening those whose risks are just beginning to re-emerge.
Funding and Clinical Data
This research was supported by grants from the National Institutes of Health (NIH) and internal institutional research funds from the participating tertiary medical center. No specific clinicaltrials.gov identifier is associated with this retrospective cohort analysis, as it utilized existing medical records and pathology databases.
References
1. Awan UA, Song Q, Ciombor KK, et al. Demographic and Clinicopathologic Factors Associated With Colorectal Adenoma Recurrence. JAMA Netw Open. 2026;9(2):e2556853. doi:10.1001/jamanetworkopen.2025.56853.
2. Gupta S, Lieberman D, Anderson JC, et al. Recommendations for Surveillance After Colonoscopy and Polypectomy: A Consensus Update by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2020;158(4):1131-1153.e5.
3. Hassan C, Antonelli G, Dumonceau JM, et al. Post-polypectomy colonoscopy surveillance: European Society of Gastrointestinal Endoscopy (ESGE) Guideline – Update 2020. Endoscopy. 2020;52(8):687-700.